Photodynamic therapy of Barrett's esophagus: Ablation of barrett's mucosa and reduction in p53 protein expression after treatment

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 485-489

  Panjehpour, Masoud ^a   Coppola, Domenico ^b   Overholt, Bergein F ^a   Vo Dinh, Tuan ^c   Overholt, Suzanne ^a  

^a THOMPSON CANCER SURVIVAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Barrett's esophagus; Dysplasia; p53; Photodynamic therapy

Indexed keywords

PHOTOFRIN; PROTEIN P53;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS BIOPSY; HUMAN; IMMUNOHISTOCHEMISTRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

BARRETT ESOPHAGUS; ESOPHAGUS; HUMANS; IMMUNOHISTOCHEMISTRY; MUCOUS MEMBRANE; PHOTOCHEMOTHERAPY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40549145517     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Overholt BF, Panjehpour M and Haydek JM: Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 49: 1-7, 1999.
2. Wang KK: Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 49(3Pt2): S20-23, 1999.
3. Kastan MB, Onyekwere O, Sidransky D et al: Participation of p53 protein in cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
4. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
5. Lowe SW, Bodis S, McClatckey A et al: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
6. Kinzler KW and Vogelstein B: Cancer therapy meets p53. New Eng J Med 331: 49-50, 1994.
7. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R and Cherian R: p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 96: 1321-1323, 2001.
8. Gimenez A, Minguela A, Parilla P, Bermejo J, Perez D, Molina J, Garcia A et al: Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 83: 641-651, 1998.
9. Gimenez A, de Haro LM, Parrilla P, Bermejo J, Perez-Guillermo M and Ortiz MA: Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett's esophagus and mild histologic alternations. Arch Pathol Lab Med 123: 1260-1263, 1999.
10. Younes M, Lebovitz RM, Lechago LV and Lechago J: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105: 1637-1642, 1993.
11. Symmans PJ, Linehan JM, Filipe B and Filipe M: p53 expression in Barrett's esophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 173: 221-226, 1994.
12. Krishnadath KK, Tilanus HW, Van Blankenstein M, Bosman FT and Mulder AH: Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 175: 175-180, 1995.
13. Polkowski W, Van Lanschot JJB, Ten Kate FJW, Baak JPA, Tytgat GNJ, Obertop H, Voorn WJ, Voorn WJ and Offerhaus GJA: The value of p53 and Ki67 as marker for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 4: 163-171, 1995.
14. Bian YS, Osterheld MC, Bosman FT, Benhattar J and Fontolliet C: p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14: 397-403, 2001.
15. Bodner SM, Minna JD, Jensen SM et al: Expression of mutant p53 protein in lung cancer correlates with the class of p53 gene mutation. Oncogene 7: 743-749, 1992.
16. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Nat Cancer Inst 85: 200-206, 1993.
17. Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R and Fass R: Biomarker studies in Reversed Barrett's esophagus. Am J Gastroenterol 94: 2829-2833, 1999.
18. Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, Lutzke LS and Liu W: Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterol 119: 624-630, 2000.
19. Khan S, Do KA, Kuhnert P, Pillay SP, Papadimos D, Conrad R and Jass JR: Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 30: 136-140, 1998
20. Prevo LJ, Sanchez CA, Galipeau PC and Reid BJ : P53-mutant clones and field effect in Barrett's esophagus. Cancer Res 59: 4784-4787, 1999.
21. Galipeau PC, Prevo LJ, Sanchez CA and Longton GM: Clonal expression and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Nat Cancer Inst 91: 2087-2095, 1999.
22. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS and Reid BJ: Evolution of neoplastic cell lineages in Barrett's Oesophagus. Nat Genet 22: 106-109, 1999.
23. Reid BJ: p53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol 96(5): 1321-1323, 2001.